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Abstract
 
Hepatitis has spread widely due to environmental pollution damaging liver cells, which need regeneration of 
hepatocytes and gradual replacement of the damaged cells. Since Calotropis gigantea is widely used in 
Ayurveda for the treatment of liver disorders, attempt was made to scientifically evaluate its 
hepatoprotective activity in rats. 
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Introduction
Calotropis gigantea R.Br. (Asclepiadaceae) is commonly known as milkweed or swallowwort. It grows 
about 1-5m high. The flowers are used as digestive, tonic, in cough, cold and asthma [1]. Plant parts have 
been reported to have antidiarrhoeal [2,3], analgesic activity [4], anti-inflammatory [5], antipyretic [6] and 
CNS depressant activity [7,8]. It contains alkaloids, tannins, phenols and resins [9,10]. Tetra and 
pentacyclic triterpenoids, cardiac glycosides [11], flavonol glycosides [12] and a non protein amino acid 
giganticine[13] have been reported. Its use in hepatitis has been illustrated in Indian System of Medicine 
[14]. The folks and Vaidyas have clinically used it successfully. But no studies have been reported on 
hepatoprotective activity yet. This motivated the biological evaluation of this activity of its flowers. 
 
Materials and Methods
Plant material
          National Herbarium of Cultivated Plants, New Delhi, authenticated the plant parts of Calotropis 
gigantea, voucher no. NHCP/NBPGR/2005/89/4072. The flowers were collected in April from Bhopal (M.
P.). They were dried in shade, coarsely powdered and macerated for 72 hrs. in alcohol (95%). The alcoholic 
extract was concentrated and suspended in vehicle (5% v/v aqueous Tween 80). This suspension of extract 
was used orally at a dose of 250 mg/kg for the evaluation of hepatoprotective activity by studying the 
biological, physical, functional and histological parameters. 
Animals
         Wistar albino rats, weighing 130-160 gm were maintained under standard conditions and diet. They 
had free access to water. The experiments were carried out by the permission of Institutional Animal Ethical 
Committee. 
 
Evaluation of hepatoprotective activity
         The activity was evaluated in three models. The rats were divided into four groups each containing six 
rats. Group I was administered 10 ml/kg b.w. of vehicle and served as control. Group II was given a dose of 
silymarin (100 mg/kg) and was marked as standard. Group III was administered a dose of 250 mg/kg of 
alcoholic extract of Calotropis gigantea flower (CGF). All the above doses were given orally. Group IV 
(toxicant) was administered 10 ml/kg of vehicle everyday and a single i.p. dose of 1.25 ml/kg b.w. CCl4 (in 
equal volume of liquid paraffin) along with other groups.
 
Model I
Prophylactic study 15
A prophylactic study was carried out by prior administration of extracts to protect the liver. The rats were 
divided into four groups as stated earlier. They were given their respective doses on first, second and third 
day. After one hour of administration of the last dose (3rd day) they were intoxicated intraperitoneally with 
1.25 ml/kg CCl4 (in equal volume of liquid paraffin), except the control group. They were anaesthetized on 
fourth day. Their blood was collected and kept at 37ºC for one hour and then centrifuged at 2000 rpm for 15 
min. The serum was collected and estimated for SGPT, SGOT, ALP and BLN. After withdrawal of blood 
from each rat the liver was carefully removed, washed with chilled normal saline, dried by soaking well on 
filter paper and weighed. (Table 1)
 
Table 1 Effect of alcoholic extract of C. gigantea flower on serumenzyme activity and weight of liver 
in CCl4 induced liver damage (Model I).
Treatment 
Group
SGPT
IU/L
SGOT
IU/L
ALP
KAU
BLN
mg/L
Weight of liver /
100 gm.
Control 41.27±1.72   67.81±1.48 35.66±1.35 0.64±0.01 3.62±0.09
Silymarin 82.62±1.88** 155.01±2.22** 71.73±2.08* 1.84±0.04* 4.68±0.15**
CGF 78.26±3.61** 140.79±2.59* 59.24±1.50* 1.33±0.03* 4.23±0.13*
Toxicant   93.06±2.65 165.72±2.04 89.67±2.73 2.14±0.03 5.23±0.12
All values are given in Mean ± SEM
*P<0. 001 and **P<0.01 as compared to toxicant.
 
Model II
Therapeutic  study15-16
The four groups of rats were taken as stated above. On the first day all the groups were administered their 
respective doses.  After 2 hrs. of dosing, all the rats were given an intraperitoneal dose of 1.25 ml/kg CCl4 
(in equal volume of liquid paraffin), except the control group. On second and third day all the groups were 
again given their respective doses. On fourth day blood was collected and studies were done as performed 
during prophylactic studies. The results are presented in Table 2. Small pieces of liver were transferred to 
Bouins fluid and used for histopathological studies Fig 1. 
 
Table 2  Effect of alcoholic extract of C. gigantea flowers on serum enzyme activity and weight of liver in CCl4 
induced liver damage (Model II).
Treatment 
Group
SGPT
IU/L
SGOT
IU/L
ALP
KAU
BLN
mg/L
Weight of 
liver /
100 gm. b.w.
Control  45.95±1.86 66.81±3.48 31.82±2.10 0.51±0.01 3.51±0.08
Silymarin 76.12±2.99** 139.86±3.67* 40.97±2.11* 1.64±0.02* 4.13±0.13**
CGF 72.48±3.24* 105.92±5.20* 39.51±2.67* 1.16±0.02* 3.84±0.14*
Toxicant 94.84±4.17 173.41±4.13 62.96±2.54 1.84±0.03 4.90±0.15
All values are given in Mean ± SEM
*P<0. 001 and **P<0.01 as compared to toxicant.
 
Model III
Effect on Pentobarbitone induced sleeping time 16-17 
The reduction in the sleeping time was used to evaluate the protection of rat liver against the CCl4 induced 
liver damage. Six groups of rats containing six rats in each group were taken as shown in table 3. On first 
day animals were given their respective doses. After two hours of treatment all animals were given CCl4. 
 On second day again all the rats were given their respective doses and one hour after treatment they were 
given pentobarbitone sodium (40 mg / kg i.p.). The onset of action and duration of sleep (loss of righting 
reflex) was noted. The results are represented in table 3.
 
Table 3 Effect of alcoholic extract of C. gigantea flower on pentobarbitone hypnosis in CCl4 induced liver 
damage in rats.
Treatment Group
Onset of sleep
(min.)
Duration of sleep (min.)
% Increase
in sleep
Control (Vehicle) 33.33±0.88 86.67±1.45 --
CGF 250 mg/kg 32.17±2.02 141.50±2.19* 63.26
CGF 250 mg/kg + CCl4 23.00±1.06 153.67±1.54* 77.30
Toxicant (CCl4 ) 15.83±1.08 189.00±2.45     118.06
All values are given in Mean ± SEM, *P<0. 001 as compared to toxicant.
 
Results
The hepatoprotective activity was adjudged from the serum parameters SGOT, SGPT, ALP and BLN. The 
results were further confirmed by pentobarbitone hypnosis, histopathological studies of liver sections and 
weight of liver of the rats.
The results of the prophylactic and curative studies (model I and II) reveal the change in the biochemical 
parameters of the CCl4 intoxicated animals whereas no such change was observed in the control. A 
significant reduction in the serum parameters and liver weight was observed in the animals treated with 
silymarin and alcoholic extract of calotropis gigantea flowers (CGF) when compared with the toxicant, 
showing hepatoprotective activity. The extract was found to be more effective than the standard drug 
silymarin.
In pentobarbitone induced sleeping time (model III), C. gigantea extract of flowers could not reduce the 
sleeping time as they have CNS depressant activity7,8 which synergise the pentobarbitone effect. Early 
onset of action and prolonged sleep was observed. However it can be inferred that C.gigantea flowers are 
hepatoprotective as duration of sleep was significant in both the groups treated with CGF.
Histological studies reveal that the liver sections of control animals showed normal hepatic architecture 
whereas the toxicant group exhibited great distortion. The sections of silymarin treated animals had slight 
distortion in the hepatic architecture with mild dilatation of central vein without congestion but the 
hepatocytes were normal.  The section of CGF treated animals revealed hepatocytes arranged in normal 
looking lobules with central vein and portal triads. The hepatocytes showed features of ballooning necrosis 
(early stage) with slightly granular cytoplasm and centrally placed nucleus. 
 
Discussion
            The injury or disease of liver can be adjudged by estimating the serum parameters like SGOT, 
SGPT, ALP and BLN. The serum level of the enzymes is increased due to cellular leakage18-20. 
Antihepatotoxic agents decrease the increased level of these enzymes21. In CCl4 induced toxicity, CCl3˚ is 
produced as a free radical. It binds to lipoprotein leading to peroxidation of lipid of endoplasmic 
reticulum22. It has been
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Fig. 1. Optical microscopy of thin sections of liver of rats ( Model II ).
reported that the sleeping time is prolonged with early onset of action in animals treated with barbiturates 
due to a decrease in its metabolism16. The standard and the extract significantly decreased the serum level 
of the enzymes. Although the sleeping time and the weight of liver was increased in the extract treated 
animals, it was less than the toxicant group. These results were further supported by the histopathological 
studies. The hepatic cells, intralobular veins and the endothelium were found to be damaged in the toxicant 
group whereas negligible damage was seen in animals treated with extract and silymarin. Thus the results of 
histopathological parameters support the biological, physical and functional parameters. The above studies 
reveal that the group of rats treated with CCl4 developed significant hepatic damage as observed from 
elevated level of specific enzymes, weight of liver, pentobarbitone hypnosis and histological studies. The 
extract treated group showed a significant protection in the serum enzyme levels. Pretreatment (prior to 
CCl4 intoxication) was found to be lesser effective than the post treatment by drugs. 
Thus we conclude that the calotropis gigantea flower extract has very good prophylactic and therapeutic 
effect. 
 
Acknowledgement
The authors are thankful to Dr. Neelkamal Kapoor, Professor and Head, Department of Pathophysiology, 
Gandhi Medical College, Bhopal.
 
References
1.      Annonymous : The Wealth of India, CSIR, New Delhi, 1992, Vol. 1, pp. 78-84.
2.      Argal, A. and Pathak, A.K., Indian Journal of Natural Products, Sep. 2005, 21(3), 42-44.
3.              Argal, A. and Pathak, A.K., Indian Drugs, Dec. 2005, 42(12), 826-828.  
4.               Rajesh, R., Gowda, R.C.D., Nataraju, A., Dhananjaya, B.L., Kemparaju, K. and 
Vishwanath, B.S., Toxicon, 2005, 46,184-192.  
5.       Argal, A. and Pathak, A.K., Indian Journal of Natural Products, Dec. 2005, 21 (4), 55-57.
6.       Chitme, H.R., Chandra, R. and Kaushik, S., Phytotherapy Research, 2005, 5, 454-456.
7.       Argal, A. and Pathak, A.K., Journal of Ethnopharmacology, 2006, 6,142-145.
8.       Argal, A. and Pathak, A.K., Indian Journal of Applied Life Sciences, vol.2, June 2006,  41-43. 
9.      Handa, S.S. and Kapoor, V.K., Pharmacognosy, 2nd Edn., Vallabh Prakashan, New Delhi, 
1989,  p. 283.
10.  Evans, W.C., Pharmacognosy, 15th Edn., W.B. Saunders, New York, 2002,  p. 471.
11.  De Sousa, D.P. and Almeida., R.N., Biogical and Pharmaceutical Bulletin, 2005, 28(2), 224-
225.  
12.   Sen, S., Sahu, N.P. and Mahato, S.B.,  Phytochemistry,  1992, 31(8), 2919-2921.
13.  Pari, K., Rao, P.J., Devakumar C. and Rastogi, J.N., Journal of Natural Products, 1998, 61, 
102-104.
14.   Gopesh, B., Sudhanidhi, Vanaushdhi Ratnakar Ank, Vol.1, Dhanvantrikaryalaya, Aligarh, 
1986, pp. 166-169. 
15.   Jadon, A., Bhadauria, M. and Shukla, S., Indian drugs, 2005, 42 (3), 136-142.
16.  Yadav, N.P. and Dixit, V.K., Journal of Ethnopharmacology, 2003, 86, 197-202.
17.   Kamat, C.D., Khandelwal, K.R., Bodhankar, S.L., Ambawade, S.D. and Mhetre, N.A., 
Journal of Natural Remedies, 2003, 3(2), 148-154.
18.  Molander, D.W., Wroblewski, F. and La Due, J.S., Clinical Research Proceedings, 1955, 3, 20-
24.
19.  Zimmerman, H.J., Kodere, Y. and West, M., Journal of Laboratory and Clinical Medicine, 
1965, 65, 315.
20.  Drotman, R.B. and Lowhorn, G.T., Toxicological sciences, 1978, 1, 163-171.
21.  Thabrew, M.I., Joice, P.D.T.M. and Rajatissa, W.A., Planta Medica, 1987, 53, 239-241.
22.  Recknagael, R., Pharmacological Review, 1967, 19, 145-196.
 
 
 
